January
22, 2007
December
18, 2006 December
11, 2006 Plymouth Pharmaceuticals™ was incorporated in 1991 under the direction of Steven A. Smith, M.D., FACP, a dermatologist; his original intent was to create a new treatment for people who suffer with psoriasis. Dr. Smith originally initiated a traditional, allopathic IND (Investigational New Drug) application process with FDA (Food & Drug Administration) to get his ORAL psoriasis medication approved for use in the United States. The term “allopathic (conventional) medicine” was coined in 1842 by Dr. Samuel Hahnemann, the father of homeopathy, and has been used ever since to distinguish “homeopathic” medicines from traditional medicines (those having gained FDA approval through an IND application). Two years after filing the IND application, Dr. Smith discovered that the main components of his psoriasis medication were already “grandfathered in” under the HPUS (Homeopathic Pharmacopoeia of the United States). The USP (United States Pharmacopoeia) is used for all allopathic medicines and dietary supplements worldwide. All ingredients, including those Dr. Smith had discovered, listed in the HPUS were already accepted by FDA as safe; therefore, Loma Lux® Psoriasis could be marketed by filing only a handful of forms with FDA. Loma Lux’s only cost would be to ramp up inventory and market the product. This allowed the company to leapfrog many of its competitors without the need for a typical IND process, which is can take up to 15 years and $300 million just to get a new drug approved by FDA. The launch of a homeopathic OTC (over the counter) psoriasis product as well as others for other diseases (acne, eczema, asthma, and sinus/allergy) came in 1996; these products were and still are sold under the Loma Lux® brand. The Loma Lux® AcnePill™ has nationwide distribution in the Target chain of stores. Most of the Loma Lux® products are also sold through various online distributors, among them www.amazon.com and www.drugstore.com. In 1999, the company launched its first homeopathic “Rx only” product, Psorizide® Ultra, to treat psoriasis, eczema, and seborrhea. Psorizide® Ultra was then reformulated for the treatment of psoriasis specifically and became Psorizide® Forte (Rx) in 2001; at that time Psorizide® Ultra’s indication became solely the treatment of eczema and seborrhea. Eczemol® (Rx) for the treatment of moderate to severe eczema, and Acunol™ (Rx), for the treatment of mild to moderate acne were launched in 2006. All prescription products are sold under the Plymouth Pharmaceuticals™ brand. Pharmaceutical Products:
Loma Lux® Consumer Health Care Products:
For more information, visit http://www.lomalux.com !=http://www.medterms.com/script/main/art.asp?articlekey=33613 |
